# NeoIpower (NCT05104788)

> A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

No report yet. It can be ordered.

- Indication: resectable stage II–IIIB EGFR-mutant lung adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05104788
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Peking University Cancer Hospital & Institute
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Icotinib; Cisplatin; Carboplatin; Pemetrexed
- Enrollment: 27
- Primary outcome: Major Pathological Response (MPR)

## Indexed commentary on NeoIpower so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=neoipower-nct05104788